Fifth Third Bancorp’s Generate Biomedicines GENB Stock Holding History

Fifth Third Bancorp’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.06K	Buy	+204	New	+$3.14K	﹤0.01%	4020

Other funds holding GENB

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return

Fifth Third Bancorp's GENB Position: Q3 2026 in Review

Fifth Third Bancorp opened a new position in Generate Biomedicines (GENB) in Q3 2026: 204 shares worth $3.06K. The stake represents ﹤0.01% of the portfolio and ranks #4020 among its holdings.

41 funds tracked by Wall St. Rank hold GENB as of Q3 2026.

Fifth Third Bancorp held 204 shares of Generate Biomedicines worth $3.06K as of Q3 2026.
Generate Biomedicines was a new Fifth Third Bancorp position in Q3 2026.
Generate Biomedicines made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q3 2026, its #4020 holding.
41 funds tracked by Wall St. Rank held Generate Biomedicines as of Q3 2026.

Based on Fifth Third Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.